Cyclosporin A Treatment is Able to Revert the Decrease in Circulating GH and IGF-I and the Increase in IGFBPs Induced by Adjuvant Arthritis

The aim of this study was to find out whether cyclosporin A administration is able to revert the decrease in circulating growth hormone (GH) and insulin-like growth factor-I (IGF-I) and the increase in IGF-binding proteins (IGFBPs) levels caused by adjuvant-induced arthritis in rats. Male Sprague-Dawley rats were intradermically injected with Freund’s adjuvant or vehicle. Fourteen days later, rats were randomly divided into two groups - one injected with cyclosporin (15 mg/kg) and the other with vehicle from day 16 to 23 after adjuvant injection. Arthritis decreased body weight gain and serum concentrations of GH. Cyclosporin administration to arthritic rats prevented both effects, whereas cyclosporin had no effect in control rats. Arthritis decreased serum concentrations of IGF-I (p < 0.01), but increased IGFBPs. Cyclosporin administration increased circulating IGF-I, and there was a negative correlation between circulating IGF-I and arthritis index scores in arthritic rats injected with cyclosporin (p < 0.05). Cyclosporin treatment did not alter serum IGFBPs levels in control rats, whereas cyclosporin administration normalised IGFBPs in arthritic rats. These results indicate that the effects of cyclosporin administration on the GH-IGF-IGFBPs system may partly mediate its beneficial effect on body weight in arthritic rats.

Immunosuppression - Cytokines - Freund’s Adjuvant - Chronic Inflammation - Somatotropic Axis - GH - IGF-I - IGFBPs

References

• 1 Rofe A M, Whithehouse M W, Bourgeois C S, Haynes D R, Vernon-Roberts B. Prevention of adjuvant-induced cachexia in rats by cyclosporin A.  Immunol Cell Biol. 1990;  68 63-69
• 2 Roubenoff R, Roubenoff R A, Cannon J G, Kehayias J J, Zhuang H, Dawson-Hughes B Dinarello C A, Rosenberg I H. Rheumatoid cachexia: cytokine-driven hypermetabolism and loss of lean body mass in chronic inflammation.  J Clin Invest. 1994;  93 2379-2386
• 3 Roubenoff R, Freeman L M, Smith D E, Abad L W, Dinarello C A, Kehayias J J. Adjuvant arthritis as a model of inflammatory cachexia.  Arthritis Rheum. 1997;  40 534-539
• 4 Van den Berghe G. Novel insights into the neuroendocrinology of critical illness.  Eur J Endocrinol. 2000;  143 1-13
• 5 Aitman T J, Palmer R G, Loftus J, Ansell B M, Royston J P, Teale J D, Clayton R N. Serum IGF-I levels and growth failure in juvenile chronic arthritis.  Clin Exp Rheumatol. 1989;  7 557-561
• 6 Davies U M, Rooney M, Preece M A, Ansell B M, Woo P. Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone.  J Rheumatol. 1994;  21 153-158
• 7 Templ E, Koeller M, Riedl M, Wagner O, Graninger W, Luger A. Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis.  British J Rheumatol. 1996;  35 350-356
• 8 López-Calderón A, Soto L, Martín A I. Chronic inflammation inhibits GH secretion and alters the serum insulin-like growth factor system in rats.  Life Sci. 1999;  65 2049-2060
• 9 Ibáñez de Cáceres I, Villanúa M A, Soto L, Martín A I, López-Calderón A. IGF-I and IGF-binding proteins in rats with adjuvant-induced arthritis given recombinant human growth hormone.  J Endocrinol. 2000;  165 537-544
• 10 Peisen J N, McDonnell K J, Mulroney S E, Lumpkin M D. Endotoxin-induced suppression of the somatotropic axis is mediated by interleukin-1β and corticotropin-releasing factor in the juvenile rats.  Endocrinology. 1995;  136 3378-3390
• 11 Thissen J P, Verniers J. Inhibition by interleukin-1 and tumor necrosis factor-α of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte culture.  Endocrinology. 1997;  138 1078-1084
• 12 Selgas L, Arce A, Esquifino A I, Cardinali D P. Twenty-four-hour rhythms of serum ACTH, prolactin, growth hormone, and thyroid-stimulating hormone, and of median-eminence norepinephrine, dopamine, and serotonin, in rats injected with Freund’s adjuvant.  Chronobiol Int. 1997;  14 253-265
• 13 Ferraccioli G, Guerra P, Rizzi V, Bartoli E. Cyclosporin A increases somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases.  J Rheumatol. 1995;  22 1060-1064
• 14 López-Calderón A, Soto L, Villanúa M A, Vidarte L, Martín A I. The effect of cyclosporine administration on growth hormone release and serum concentrations of insulin-like growth factor-I in male rats.  Life Sci. 1999;  65 2049-2066
• 15 Tanaka H, Ueta Y, Yamashita U, Kannan H, Yamashita H. Biphasic changes in behavioral, endocrine, and sympathetic systems in adjuvant arthritis in Lewis rats.  Brain Res Bull. 1996;  39 33-37
• 16 Vara E, Tamarit-Rodriguez J. Islet secretion of immunoreactive thyrotropin-releasing hormone and the “paracrine-like” effects of its exogenous administration.  Acta Endocrinol. 1988;  118 429-436
• 17 Cattel V, Cook T, Moncada S. Glomeruli synthesize nitrite in experimental nephrotoxic nephritis.  Kidney Int. 1990;  38 1056-1060
• 18 Borel J F, Weisinger D, Gubler H U. Effect of the anti-lymphocyte agent cyclosporin A in chronic inflammation.  Eur J Rheumatol Inflamm. 1978;  1 237-241
• 19 del Pozo E, Graeber M, Elford P, Payne T. Regression of bone and cartilage loss in adjuvant arthritis rats after treatment with cyclosporin A.  Arthritis Rheum. 1990;  33 247-252
• 20 del Pozo E, Zapf J. Skeletal growth and bone density as sensitive parameters in experimental arthritis: effect of cyclosporin A.  Bone. 1994;  15 625-628
• 21 Jiang H, Yang X, Soriano R N, Fujimura T, Krishnan K, Kobayashi M. Distinct patterns of cytokine gene suppression by the equivalent effective doses of cyclosporine and tacrolimus in rat heart allografts.  Immunobiol. 2000;  202 280-292
• 22 Ohye H, Sato M, Murao K, Matsubara S, Tokuda M, Takahara J. Cellular signalling mechanism for stimulation of growth hormone secretion and growth hormone primary transcripts by immunosuppressant agents, FK506 and cyclosporin A, in cultured rat pituitary cells.  Neuroimmunomodulat. 1998;  5 309-317
• 23 Antoni F A, Shipston M J, Smith S M. Inhibitory role for calcineurin in stimulus-secretion coupling revealed by FK506 and cyclosporin A in pituitary corticotrope tumor cells.  Biochem Baffies Res Co. 1993;  194 226-233
• 24 Anton F A, Barnard R AO, Skipton M L, Smith S M, Simpson J, Paterson J M. Calcineurin feedback inhibition of agonist-evoked CAMP formation.  J Biol Chem. 1995;  270 28 055-28 061
• 25 Menegazo L A, Ursich M L, Fukui R T, Rocha D M, Silva M E, Ianhez L E, Sabbaga E, Wajchenberg B L. Mechanism of the diabetogenic action of cyclosporin A.  Horm Metab Res. 1998;  30 663-667
• 26 Stephanou A, Sarlis N J, Knight R A, Lightman S L, Chowdrey S. Effects of cyclosporine A on the hypothalamic-pituitary-adrenal axis and anterior pituitary interleukin-6 mRNA expression during chronic inflammatory stress in the rat.  J Neuroendocrinol. 1992;  41 215-222
• 27 Thakore J H, Dinan T G. Growth hormone secretion: the role of glucocorticoids.  Life Sci. 1994;  55 1083-1099
• 28 Fernihough J K, Billingham M E, Cwyfan-Hughes S, Holly J M. Local disruption of the insulin-like growth factor system in the arthritic joint.  Arthritis Rheum. 1996;  39 1556-1565
• 29 Matsumoto T, Gargosky S E, Iwasaki K, Rosenfeld R G. Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid.  J Endocrinol Metab. 1996;  81 150-155
• 30 Wu A, Kurarasch R, Katz J, Fox P, Baum B, Atkinson J. Effect of TNFα and INFγ on the growth of HSG cell line.  J Cell Physiol. 1994;  161 217-226
• 31 Katz J, Nasatzky E, Werner H, Le Roith D, Shemer J. Tumor necrosis factor α and interferon γ-induced cell growth arrest is mediated via insulin-like growth factor binding protein-3.  Growth Horm IGF Res. 1999;  9 174-178
• 32 Sunic D, Mc Neil J D, Rayner T E, Andress D L, Belford D A. Regulation of insulin-like growth factor-binding protein-5 by insulin-like growth factor I and interleukin-1α in ovine articular chondrocytes.  Endocrinology. 1998;  139 2356-2362
• 33 Olney R C, Tsuchiya K, Wilson D M, Mohtai M, Maloney W J, Schurman D J, Smith R L. Chondrocytes from osteoarthritic cartilage have increased expression of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) and -5, but not IGF-II or IGFBP-4.  J Clin Endocr Metab. 1996;  81 1096-1103
• 34 Tardif G, Reboul P, Pelletier J P, Geng C, Cloutier J M, Martel Pelletier J. Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding proteins.  Arthritis Rheum. 1996;  39 968-978
• 35 Whellams E J, Maile L A, Fernihough J K, Billinham M EJ, Holly J M. Alterations in insulin-like growth factor binding protein-3 proteolysis and complex formation in the arthritic joint.  J Endocrinol. 2000;  165 537-544
• 36 Oh Y. IGFBPs and neoplasic models.  Endocrine. 1997;  7 111-113
• 37 Rosen C J, Pollak M. Circulating IGF-I: New perspectives for a new century.  Trends Endocrin Metab. 1999;  10 136-141
• 38 Brauer R, Kette H, Henzgen S, Thoss K. Influence of cyclosporin A on cytokine levels in synovial fluid and serum of rats with antigen-induced arthritis.  Agents Act. 1994;  41 96-98
• 39 Fan J, Char D, Bagby G J, Gelato M C, Lang C H. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor.  Am J Physiol. 1995;  269 1204-1212
• 40 Benbassat C A, Lazarus D D, Cichy S B, Evans T M, Moldawer L L, Lowry S F. Interleukin-1 alpha (IL-1 alpha) and tumor necrosis factor alpha (TNF alpha) regulate insulin-like growth factor binding protein-1 (IGFBP-1) levels and mRNA abundance in vivo and in vitro.  Horm Metab Res. 1999;  31 209-215